These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 31226541

  • 1. Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib.
    Tomlinson SB, Sandwell S, Chuang ST, Johnson MD, Vates GE, Reagan PM.
    Leuk Res; 2019 Aug; 83():106164. PubMed ID: 31226541
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib.
    Reed DR, Hall RD, Gentzler RD, Volodin L, Douvas MG, Portell CA.
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e247-e250. PubMed ID: 30992232
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of Relapsed and Refractory ALK-Positive Anaplastic Large Cell Lymphoma With ALK-Specific Tyrosine Kinase Inhibitor in Children: A Case Series.
    Shen D, Song H, Zhang J, Liao C, Wang Y, Fang M, Tang Y.
    J Pediatr Hematol Oncol; 2022 Jan 01; 44(1):e1-e4. PubMed ID: 33661174
    [Abstract] [Full Text] [Related]

  • 4. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.
    Fukano R, Mori T, Sekimizu M, Choi I, Kada A, Saito AM, Asada R, Takeuchi K, Terauchi T, Tateishi U, Horibe K, Nagai H.
    Cancer Sci; 2020 Dec 01; 111(12):4540-4547. PubMed ID: 33010107
    [Abstract] [Full Text] [Related]

  • 5. YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation.
    Tsuji T, Ozasa H, Aoki W, Aburaya S, Yamamoto Funazo T, Furugaki K, Yoshimura Y, Yamazoe M, Ajimizu H, Yasuda Y, Nomizo T, Yoshida H, Sakamori Y, Wake H, Ueda M, Kim YH, Hirai T.
    Nat Commun; 2020 Jan 03; 11(1):74. PubMed ID: 31900393
    [Abstract] [Full Text] [Related]

  • 6. Successful Drug Rechallenge Following Severe Acute Alectinib-induced Interstitial Lung Disease in a Patient With Advanced ALK-rearranged Lung Adenocarcinoma.
    Gadotti LL, Nogueira Amorim Canedo FS, Ribeiro MFSA, Sacardo KP, Saddi R, Machado Alessi JV, de Abreu Testagrossa L, Katz A.
    Clin Lung Cancer; 2021 May 03; 22(3):e481-e486. PubMed ID: 32771343
    [No Abstract] [Full Text] [Related]

  • 7. Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.
    Kim D, Koh Y, Yoon SS.
    Anticancer Res; 2020 Mar 03; 40(3):1395-1403. PubMed ID: 32132036
    [Abstract] [Full Text] [Related]

  • 8. Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
    Gadgeel S, Shaw AT, Barlesi F, Crinò L, Yang JC, Dingemans AC, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Kotb A, Ou SI.
    Br J Cancer; 2018 Jan 03; 118(1):38-42. PubMed ID: 29149104
    [Abstract] [Full Text] [Related]

  • 9. Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung.
    Balzer BWR, Loo C, Wegner EA, Nath CE, Lee S, Smith C, Lewis CR, Trahair TN, Anazodo AC.
    Pediatr Hematol Oncol; 2018 Jan 03; 35(7-8):415-421. PubMed ID: 30526220
    [Abstract] [Full Text] [Related]

  • 10. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
    Ito K, Hataji O, Kobayashi H, Fujiwara A, Yoshida M, D'Alessandro-Gabazza CN, Itani H, Tanigawa M, Ikeda T, Fujiwara K, Fujimoto H, Kobayashi T, Gabazza EC, Taguchi O, Yamamoto N.
    J Thorac Oncol; 2017 Feb 03; 12(2):390-396. PubMed ID: 27498387
    [Abstract] [Full Text] [Related]

  • 11. Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.
    Tomasini P, Egea J, Souquet-Bressand M, Greillier L, Barlesi F.
    Ther Adv Respir Dis; 2019 Feb 03; 13():1753466619831906. PubMed ID: 30786826
    [Abstract] [Full Text] [Related]

  • 12. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
    Nishio M, Nakagawa K, Mitsudomi T, Yamamoto N, Tanaka T, Kuriki H, Zeaiter A, Tamura T.
    Lung Cancer; 2018 Jul 03; 121():37-40. PubMed ID: 29858024
    [Abstract] [Full Text] [Related]

  • 13. Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib.
    Carneiro BA, Pamarthy S, Shah AN, Sagar V, Unno K, Han H, Yang XJ, Costa RB, Nagy RJ, Lanman RB, Kuzel TM, Ross JS, Gay L, Elvin JA, Ali SM, Cristofanilli M, Chae YK, Giles FJ, Abdulkadir SA.
    Clin Cancer Res; 2018 Jun 15; 24(12):2732-2739. PubMed ID: 29559559
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer.
    Yoshida H, Kim YH, Ozasa H, Sakamori Y, Tsuji T, Nomizo T, Yasuda Y, Yamamoto T, Ajimizu H, Hirai T.
    In Vivo; 2018 Jun 15; 32(6):1587-1590. PubMed ID: 30348720
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma with MYC rearrangement.
    Khanlari M, Tang G, Hao S, Gong Y, Li S, Miranda RN, Lin P, Iyer S, Yin CC, Xie W, Vega F, Medeiros LJ, Xu J.
    Br J Haematol; 2021 Jan 15; 192(1):e17-e21. PubMed ID: 33216956
    [No Abstract] [Full Text] [Related]

  • 18. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
    Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW.
    J Clin Oncol; 2016 Mar 01; 34(7):661-8. PubMed ID: 26598747
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. "Double hit" anaplastic large cell lymphoma with concurrent ALK and MYC rearrangements.
    Luo DX, Li W, Ye MT, Yang Y, Tang G, You MJ.
    Am J Hematol; 2020 Dec 01; 95(12):1625-1627. PubMed ID: 32833271
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.